Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary 

Rhea-AI Summary

Advanced Biomed (Nasdaq: ADVB) announced on Dec 30, 2025 that it sold 100% of Advanced Biomed (HK) Limited to buyer Wei Ha Hui with closing on Dec 23, 2025.

The aggregate purchase price was US$23,000 based on a company-commissioned valuation report. All intellectual property held by the Hong Kong subsidiary, including IP owned by Shanghai Sglcell Biotech Co., Ltd., transferred to the buyer at closing. Management said the divestiture responds to evolving China clinical-data regulations and that all clinical trials will be centralized and conducted through the Taiwan subsidiary as part of a strategic realignment.

Positive

• Sale closed on Dec 23, 2025 for immediate cash consideration of US$23,000
• Clinical trials centralized to Taiwan subsidiary to streamline operations

Negative

• All intellectual property of the Hong Kong and Shanghai subsidiaries transferred to buyer at closing
• Divestiture reduces presence in Hong Kong/China operations and related assets

News Market Reaction – ADVB

+1.50%

9 alerts

+1.50% News Effect

+2.3% Peak Tracked

-20.5% Trough Tracked

+$115K Valuation Impact

$8M Market Cap

0.1x Rel. Volume

On the day this news was published, ADVB gained 1.50%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.3% during that session. Argus tracked a trough of -20.5% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $115K to the company's valuation, bringing the market cap to $8M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Subsidiary sale price: US$23,000 Net loss (quarter): $386,901 Operating expenses: $523,914 +5 more

8 metrics

Subsidiary sale price US$23,000 Aggregate purchase price for 100% of Hong Kong subsidiary shares on Dec 23, 2025

Net loss (quarter) $386,901 Three months ended Sep 30, 2025 (vs. $265,580 prior year)

Operating expenses $523,914 Three months ended Sep 30, 2025 (R&D $235,992; G&A $287,922)

Cash balance $2,656,519 As of Sep 30, 2025

Total liabilities $3,238,846 As of Sep 30, 2025 (vs. stockholders’ equity $3,004,124)

IPO gross proceeds $6.56 million March 2025 IPO, per 10-Q disclosure

Equity line capacity $25,000,000 Equity line of credit for common stock sales, disclosed in 10-Q

Annual net loss $3,258,969 Full year, per 10-K filing

Market Reality Check

Price: $4.06 Vol: Volume 119,253 is 0.08x t...

low vol

$4.06 Last Close

Volume Volume 119,253 is 0.08x the 20-day average 1,452,547, indicating limited pre-news trading interest. low

Technical Price $0.3336 is below the 200-day MA $0.98 and near the 52-week low of $0.31 (vs. high $4.10).

Peers on Argus

Within Services-medical Laboratories/Diagnostics & Research, peers show mixed bu...

1 Up 2 Down

Within Services-medical Laboratories/Diagnostics & Research, peers show mixed but generally weak action: ISPC -8.07%, MYNZ -4.72%, XWEL -2.55%, PRPH -10%, while BIAF is up 1.74%. Momentum data highlight ISPC -7.72%, XWEL -7.03% (down) and BIAF +5.14% (up), suggesting broader volatility in the group.

Historical Context

1 past event · Latest: Sep 19 (Positive)

Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Sep 19	Product launch	Positive	-17.2%	Launch of A+PerfusC™ 3D cell culture platform for precision medicine and drug discovery.

Pattern Detected

The prior product launch on Sep 19, 2025 saw a negative -17.18% reaction despite a technology-focused, growth-oriented announcement, indicating a tendency for weak price responses even to seemingly constructive news.

Recent Company History

Over the last six months, Advanced Biomed reported a key product launch and ongoing operational losses. On Sep 19, 2025, it launched the A+PerfusC™ 3D cell culture platform targeting the global 3D cell culture market, valued at $2.32 billion in 2025 and projected to reach $4.71 billion by 2030. Despite the strategic nature of that news, the stock fell 17.18% over 24 hours, showing a divergence between positive operational updates and share-price performance. Today’s divestiture follows that backdrop of weak historical reactions.

Market Pulse Summary

This announcement details the divestiture of Advanced Biomed’s Hong Kong subsidiary and transfer of ...

Analysis

This announcement details the divestiture of Advanced Biomed’s Hong Kong subsidiary and transfer of related IP for US$23,000, alongside a shift of clinical trials to its Taiwan subsidiary in response to evolving China regulations. In context, the company recently reported a quarterly net loss of $386,901 and annual net loss of $3,258,969, with management citing substantial doubt about going concern. Investors may watch execution of the new trial hub strategy and use of the $25,000,000 equity line.

Key Terms

precision medicine, clinical trials, equity line of credit, circulating tumor cell, +2 more

6 terms

precision medicine medical

"innovative biomedical products for precision medicine and advanced diagnostics"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

clinical trials medical

"In light of evolving regulatory requirements on clinical trials and data in China"

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

equity line of credit financial

"an equity line of credit allowing sales of up to $25,000,000 of common stock"

An equity line of credit is a loan that allows homeowners to borrow money against the value of their property, similar to having a flexible credit card secured by their home. It matters to investors because it provides a way for property owners to access cash for various needs, which can influence real estate markets and overall economic activity. This type of credit offers ongoing borrowing capacity, making it a valuable financial tool for those with significant property equity.

circulating tumor cell medical

"technology for circulating tumor cell (CTC) capture, identification and single‑cell isolation"

A circulating tumor cell is a rare cancer cell that has broken away from a tumor and is traveling in the bloodstream; unlike ordinary blood cells, these cells can seed new tumors elsewhere in the body. Investors care because tests or therapies that detect, track or eliminate these cells can improve how doctors monitor disease, pick treatments and measure drug effect — like spotting a few seeds floating downstream that reveal whether and where a garden is spreading.

microfluidic technical

"built on a proprietary microfluidic platform and ultra‑sensitive biosensor technology"

Microfluidic describes technology that controls and moves extremely small amounts of liquids through tiny channels on a chip, like a miniature plumbing system for droplets. It matters to investors because it can cut the time, cost and materials needed for medical tests, drug discovery and small-scale manufacturing, potentially creating faster product development, lower production costs and new revenue opportunities for companies using the technology.

biosensor technical

"proprietary microfluidic platform and ultra‑sensitive biosensor technology"

A biosensor is a device that detects biological signals—such as proteins, DNA, or metabolites—and converts them into readable electronic or visual data, like a smoke detector that senses a problem and triggers a readable alert. For investors it matters because biosensors can enable faster, cheaper, and more frequent medical tests or environmental monitoring, creating sales, recurring consumable demand, and potential regulatory milestones that can materially affect a company’s revenue and valuation.

AI-generated analysis. Not financial advice.

Tainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced that on December 23, 2025, it entered into an agreement (the “Agreement”) with an unrelated third party, Wei Ha Hui (the “Buyer”), pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company and a wholly owned subsidiary of the Company (the “Hong Kong Subsidiary”), for an aggregate purchase price of US$23,000 based on a valuation report commissioned by the Company, subject to the terms and conditions set forth in the Agreement.

All intellectual property owned by the Hong Kong subsidiary, including intellectual property owned by Shanghai Sglcell Biotech Co., Ltd., a wholly owned subsidiary of the Hong Kong subsidiary, was transferred to the Buyer at the closing of this transaction on December 23, 2025.

Dr. Yi Lu, CEO of the Company, commented: “In light of evolving regulatory requirements on clinical trials and data in China, and to accelerate development and commercialization of our products and solutions, we decided to divest the assets of Hong Kong and Shanghai subsidiaries. All clinical trials will now be centralized and conducted through our Taiwan subsidiary, which we believe will be part of our strategic realignment.”

About Advanced Biomed Inc.

Advanced Biomed Inc. is a Nevada corporation specializing in innovative biomedical technologies for cancer detection and precision medicine.

Operating through the subsidiary in Taiwan, the Company has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology to enable advanced circulating tumor cell (CTC) detection, enrichment, and analysis. Its portfolio includes devices, biochips, and designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for future global expansion.

For more information, please visit: www.advanbiomed.com.

Forward‑Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the documents filed with the United States Securities and Exchange Commission (the “SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
Advanced Biomed Inc.
Steven I-Fang Cheng
Email: info@advbiomedicine.com
invest@advbiomedicine.com

FAQ

What did Advanced Biomed (ADVB) sell on Dec 23, 2025?

Advanced Biomed sold 100% of Advanced Biomed (HK) Limited to Wei Ha Hui for US$23,000, with closing on Dec 23, 2025.

Did Advanced Biomed (ADVB) transfer intellectual property in the sale?

Yes; all intellectual property of the Hong Kong subsidiary, including IP owned by Shanghai Sglcell Biotech Co., Ltd., transferred to the buyer at closing.

Why did Advanced Biomed (ADVB) divest its Hong Kong subsidiary?

Management cited evolving regulatory requirements on clinical trials and data in China and said the move supports accelerated development and commercialization.

Where will Advanced Biomed (ADVB) run clinical trials after the sale?

The company said all clinical trials will be centralized and conducted through its Taiwan subsidiary going forward.

Who is the buyer of Advanced Biomed (HK) Limited in the ADVB transaction?

The buyer is identified as Wei Ha Hui, an unrelated third party named in the agreement.